The laboratories at Lifeblood perform a range of tests on all donations to:
- allow appropriate selection of blood for transfusion e.g. to ensure ABO compatibility between donor and recipient
- identify donors whose donations aren’t suitable for transfusion e.g. donors who carry transfusion-transmissible infections, and
- minimise or prevent adverse consequences of transfusion.
Mandatory testing of fresh blood components for transfusion are:
- ABO and RhD blood groups
- red cell antibody screening
- syphilis serology
- viral screening for:
- Human Immunodeficiency virus (HIV) 1 and 2 antibodies and RNA
- Hepatitis B virus (HBV) surface antigen and HBV DNA
- Hepatitis C virus (HCV) antibodies and HCV RNA
All apheresis platelet collections and buffy coat derived pooled platelets are sampled for bacterial contamination screening at or after 36 hours post collection.
When required, additional donation testing is performed, including confirmatory testing, and screening for antibodies to CMV, human T-lymphotropic virus (HTLV) and malaria.
Lifeblood has strict guidelines and standard operating procedures for these tests which are all performed in TGA licensed facilities accredited for good laboratory and manufacturing practices.
Test results are always checked before blood components are released for clinical use or further manufacture.
If a screening test for infectious disease is confirmed reactive, and the donation is destroyed, and donor is notified and counselled as part of standard Lifeblood procedures.
Components are only labelled for release when:
- donor selection criteria have been met
- mandatory viral screening is non-reactive
- blood grouping results have been confirmed
- red cell antibody screening is complete, and
- product quality is acceptable as per defined component specifications.
Donations collected exclusively for plasma fractionation undergo infectious diseases screening for HIV, HBV and HCV but are not tested for HTLV 1/2, syphilis or a blood group, and an antibody screen is only performed if the donor was transfused or pregnant since last donating.
CSL Behring engaged an external laboratory to perform hepatitis A and parvovirus B19 nucleic acid testing (NAT) on plasma supplied by Lifeblood, for plasma quality assurance release testing, from April 2025. All donations undergo this additional testing. Hepatitis A and parvovirus B19 are not release tests for fresh component transfusion. Lifeblood is notified of positive results and performs product recall and clinician notification where the component has been transfused.
Updated April 2025
